



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/602,136 Confirmation No.: Unassigned  
Applicant: Sommadossi *et al.*  
Filed: June 20, 2003  
TC/AU.: Unassigned  
Examiner: Unassigned  
  
Docket No.: 06171.105074 IDX 1007 DIV  
Customer No.: 20786  
Title: Methods and Compositions for Treating Hepatitis C Virus

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

**Transmittal of Information Disclosure Statement**

Sir:

The citation of information on the attached Form PTO-1449 is made pursuant to 37 C.F.R. §§ 1.56, 1.97, and 1.98. Copies of all references are enclosed. The citation of this information does not constitute an admission of priority or that any cited item is available as a reference, or a waiver of any right the applicant may have under applicable statutes, Rules of Practice in patent cases, or otherwise.

Because this Information Disclosure Statement is being submitted before the mailing of a first Office action on the merits, the Applicants do not believe that any additional fees are due; however, the Commissioner is hereby authorized to charge any fees due or credit any overpayment to Deposit Account No. 11-0980.

Respectfully submitted,

Sherry M. Knowles, Esq.  
Reg. No. 33,052

King & Spalding, LLP  
191 Peachtree Street, N.E., Atlanta, GA 30303  
Office: (404)572-4600/ Fax: 404-572-5145

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in 2 boxes addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on March 2, 2004.

Jennifer A. Williams

3425-06\_1.DOC

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

6

## Complete if Known

Application Number	10/602,136
Filing Date	June 20, 2003
First Named Inventor	Sommadossi <i>et al.</i>
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	06171.105074 IDX 1007 DIV

3424454 2

## U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pgs, Clmns, Lns, Where Relevant Passages/Relevant Figs Appear
		Number	Kind Code (if known)			
AA	3,480,613	A		Walton <i>et al.</i>	11-25-1969	
AB	5,977,061	A		De Clercq	11-02-1999	
AC	6,340,690	B1		Bachand <i>et al.</i>	01-22-2002	
AD	6,348,587	B1		Schinazi <i>et al.</i>	02-2002	
AE	6,395,716	B1		Gosselin <i>et al.</i> (Novirio / Idenix)	05-28-2002	
AF	6,444,652	B1		Gosselin <i>et al.</i> (Novirio / Idenix)	09-03-2002	
AG	6,573,248	B1		Ramasamy <i>et al.</i>	06-03-2003	
AH	2002/0019363	A1		Ismaili <i>et al.</i>	02-2002	
AI	2002/0055483	A1		Watanabe <i>et al.</i>	05-09-2002	
AJ	2002/0147160	A1		Bhat <i>et al.</i>	10-10-2002	
AK	2003/008841	A1		Devos <i>et al.</i>	01-09-2003	
AL	2003/028013	A1		Wang <i>et al.</i>	02-06-2003	
AM	2003/0050229	A1		Sommadossi <i>et al.</i>	03-13-2003	
AN	2003/0060400	A1		LaColla <i>et al.</i>	03-27-2003	
AO	2003/0083307	A1		Devos <i>et al.</i>	05-01-2003	
AP	2003/0087873	A1		Stuyver <i>et al.</i>	05-08-2003	

## FOREIGN PATENT DOCUMENTS


Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number				
AQ	FR	1,521,076	A	Merck & Co. Inc.	04-12-1968		
AR	FR	1,581,628	A	Merck & Co. Inc.	09-19-1969		
AS	FR	2,662,165	A	Univ. Paris Curie	11-22-1991		
AT	GB	1,163,103	A	Merck & Co. Inc.	09-04-1969		
AU	GB	1,209,654	A	Merck & Co. Inc.	10-21-1970		
AV	JP	63-215694	A	Yamasa Shoyu Co. Ltd.	09-08-1988		
AW	JP	06-228186	A	Yamasa Shoyu Co. Ltd.	08-16-1994		
AX	WO	98/16184	A2	ICN Pharmaceuticals	04-23-1998		
AY	WO	99/43691	A1	Emory U.; U.Ga.R.F.	02-09-1999		
AZ	WO	00/09531	A2	Novirio Pharm. (Idenix)	02-24-2000		
AAA	WO	01/32153	A2	Biochem Pharma	05-10-2001		

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	2	of	6	Attorney Docket Number	06171.105074 IDX 1007 DIV
-------	---	----	---	------------------------	---------------------------

3424454 2

## FOREIGN PATENT DOCUMENTS


Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD- YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number	Kind Code <sup>2</sup> (if known)				
BA	WO	01/60315	A2		Biochem Pharma	08-23-2001		
BB	WO	01/68663	A1		ICN Pharmaceuticals	09-20-2001		
BC	WO	01/79246	A2		Pharmasset	10-25-2001		
BD	WO	01/90121	A2		Novirio Pharm. (Idenix)	11-29-2001		
BE	WO	01/91737	A2		Novirio Pharm. (Idenix)	06-12-2001		
BF	WO	01/92282	A2		Novirio Pharm. (Idenix)	06-12-2001		
BG	WO	01/96353	A2		Novirio Pharm. (Idenix)	12-20-2001		
BH	WO	02/03997	A1		ICN Pharmaceuticals	01-17-2002		
BI	WO	02/18404	A2		F. Hoffmann-La Roche	03-07-2002		
BJ	WO	02/32920	A2		Pharmasset	04-25-2002		
BK	WO	02/48165	A2		Pharmasset	06-20-2002		
BL	WO	02/057287	A2		Merck & Co. Inc.	07-25-2002		
BM	WO	02/057425	A2		Merck & Co. Inc.	07-25-2002		
BN	WO	02/070533	A2		Pharmasset	09-12-2002		
BO	WO	02/094289	A1		F. Hoffmann-La Roche	11-28-2002		
BP	WO	02/100415	A2		F. Hoffmann-La Roche	12-19-2002		
BQ	WO	03/026589	A2		Idenix; CNRS; U. Montp.	04-03-2003		
BR	WO	03/026675	A1		Idenix; CNRS; U. Montp.	04-03-2003		
BS	WO	03/051899	A1		Ribapharm	06-26-2003		
BT	WO	03/061385	A1		Ribapharm	07-31-2003		
BU	WO	03/061576	A2		Ribapharm	07-31-2003		
BV	WO	03/062255	A2		Ribapharm	07-31-2003		
BW	WO	03/062256	A1		Ribapharm	07-31-2003		
BX	WO	03/062257	A1		Ribapharm	07-31-2003		
BY	WO	03/063771	A2		Pharmasset	08-07-2003		
BZ	WO	03/068162	A2		Pharmasset	08-21-2003		
BAA	WO	03/072757	A2		Biota Inc.	09-04-2003		
BAB	WO	03/093290	A2		Genelabs Technologies	11-13-2003		
BAC	WO	04/002422	A2		Idenix; Univ.D.S.Cagliari	01-08-2004		
BAD	WO	04/002999	A2		Idenix; Univ.D.S.Cagliari	01-08-2004		

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

10/602,136

June 20, 2003

Sommadossi *et al.*

Unassigned

Unassigned

Sheet	3	of	6	Attorney Docket Number	06171.105074 IDX 1007 DIV
-------	---	----	---	------------------------	---------------------------

3424454 2

## OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS


Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. <sup>2</sup>	T <sup>3</sup>
	CA	ALTMANN <i>et al.</i> , "The synthesis of 1'-methyl carbocyclic thymidine and its effect on nucleic acid duplex stability," <i>Synlett, Thieme Verlag, Stuttgart, De</i> , 10:853-855 (1994).	
	CB	BAGINSKI, S. G. <i>et al.</i> , "Mechanism of action of a pestivirus antiviral compound," <i>PNAS USA</i> , 97(14):7981-7986 (2000).	
	CC	BEIGELMAN, L.N., <i>et al.</i> , "Epimerization during the acetolysis of 3-O-acetyl-5-O-benzoyl-1,2-O-isopropylidene-3-C-methyl- $\alpha$ ,D-ribofuranose. Synthesis of 3'-C-methylnucleosides with the $\beta$ -D-ribo- and $\alpha$ -D-arabino configurations," <i>Carbohydrate Research</i> , 181:77-88 (1988).	
	CD	BEIGELMAN, L.N., <i>et al.</i> , "A general method for synthesis of 3'-C-alkylnucleosides," <i>Nucleic Acids Symp. Ser.</i> , 9:115-118 (1981).	
	CE	BERENGUER, M., <i>et al.</i> , "Hepatitis B and C viruses: Molecular identification and targeted antiviral therapies," <i>Proceedings of the Association of American Physicians</i> , 110(2), 98-112 (1998).	
	CF	CARROLL, S.S., <i>et al.</i> , "Inhibition of hepatitis C virus RNA replication by 2'-modified nucleoside analogs," <i>The Journal of Biological Chemistry</i> , 278(14):11979-11984 (2003).	
	CG	CZERNECKI, S., <i>et al.</i> , "Synthesis of various 3'-branched 2',3'-unsaturated pyrimidine nucleosides as potential anti-HIV agents," <i>J. Org. Chem.</i> , 57:7325-7328 (1992).	
	CH	DE FRANCESCO, R., <i>et al.</i> , "Approaching a new era for hepatitis C virus therapy: Inhibitors of the NS3-4A serine protease and the NS5B RNA-dependent RNA polymerase," <i>Antiviral Research</i> , 58:1-16 (2003).	
	CI	FAIVRE-BUET, V., <i>et al.</i> , "Synthesis of 1'-deoxypsicofuranosyl-deoxynucleosides as potential anti-HIV agents," <i>Nucleosides &amp; Nucleotides</i> , 11(7):1411-1424 (1992).	
	CJ	FARKAS, J., <i>et al.</i> , "Nucleic acid components and their analogues. XCIV. Synthesis of 6-amino-9-(1-deoxy- $\beta$ -D-psicofuranosyl)purine", <i>Collect. Czech. Chem. Commun.</i> 32:2663-2667 (1967).	
	CK	FARKAS, J., <i>et al.</i> , "Nucleic acid components and their analogues. LXXIX. Synthesis of methyl 1-deoxy-D-psicofuranosides substituted at C <sub>(1)</sub> with halo atoms or a mercapto group," <i>Collect. Czech. Chem. Commun.</i> , 31:1535-1543 (1996).	
	CL	FEDOROV, I.I., <i>et al.</i> , "3'-C-Branched 2'-deoxy-5-methyluridines: Synthesis, enzyme inhibition, and antiviral properties," <i>J. Med. Chem.</i> , 35(24):4567-4575 (1992).	
	CM	FRANCHETTI, P., <i>et al.</i> , "2'-C-Methyl analogues of selective adenosine receptor agonists: synthesis and binding studies," <i>J. Med. Chem.</i> , 41(10):1708-1715 (1998).	
	CN	GROUILLER, A., <i>et al.</i> , "Novel p-toluenesulfonylation and thionocarbonylation of unprotected thymine nucleosides," <i>Synlett</i> , 1993, 221-222 (March 1993).	
	CO	HARAGUCHI, K., <i>et al.</i> , "Preparation and reactions of 2'- and 3'- vinyl bromides of uracil nucleosides: Versatile synthons for anti-HIV agents," <i>Tetrahedron Letters</i> , 32(28):3391-3394 (1991).	

Examiner Signature		Date Considered
--------------------	--	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

## Complete if Known

Application Number

10/602,136

Filing Date

June 20, 2003

First Named Inventor

Sommadossi *et al.*

Group Art Unit

Unassigned

Examiner Name

Unassigned

Attorney Docket Number

06171.105074 IDX 1007 DIV

Sheet

4

of

6

3424454 2

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. <sup>2</sup>	T <sup>3</sup>
	DA	HARAGUCHI, K., <i>et al.</i> , "Stereoselective synthesis of 1'-C-branched uracil nucleosides from uridine," <i>Nucleosides &amp; Nucleotides</i> , 14(3-5):417-420 (1995).	
	DB	HARRY-O'KURU, R.E., <i>et al.</i> , "A short, flexible route toward 2'-C-branched ribonucleosides", <i>J.Org. Chem.</i> , 62:1754-1759 (1997). (Scheme 11).	
	DC	HARRY-O'KURU, R.E., <i>et al.</i> , "2'-C-Alkylribonucleosides: Design, synthesis, and conformation," <i>Nucleosides &amp; Nucleotides</i> , 16(7-9):1457-1460 (1997). ["Rogers" in #2; correct name in #7]	
	DD	HATTORI, H., <i>et al.</i> , "Nucleosides and nucleotides. 175. Structural requirements of the sugar moiety for the antitumor activities of new nucleoside antimetabolites, 1-(3-C-ethynyl-b-D-ribo-pentofuranosyl)cytosine and -uracil," <i>J. Med. Chem.</i> , 41:2892-2902 (1998).	
	DE	HREBABECKY, H., <i>et al.</i> , "Nucleic acid components and their analogues. CXLIX. Synthesis of pyrimidine nucleosides derived from 1-deoxy-D-psicose," <i>Collect. Czech. Chem. Commun.</i> , 37:2059-2065 (1972).	
	DF	HREBABECKY, H., <i>et al.</i> , "Synthesis of 7- and 9 $\beta$ -D-psicofuranosylguanine and their 1'-deoxy derivatives," <i>Collect. Czech. Chem. Commun.</i> , 39:2115-2123 (1974).	
	DG	IINO, T., <i>et al.</i> , "Nucleosides and nucleotides. 139. Stereoselective synthesis of (2'S)-2'-C-alkyl-2'-deoxyuridines," <i>Nucleosides and Nucleotides</i> , 15(1-3):169-181 (1996).	
	DH	ITOH, Y., <i>et al.</i> , "Divergent and stereocontrolled approach to the synthesis of uracil nucleosides branched at the anomeric position," <i>J. Org. Chem.</i> , 60(3):656-662 (1995).	
	DI	JOHNSON, C.R., <i>et al.</i> , "3'-C-Trifluoromethyl ribonucleosides," <i>Nucleosides &amp; Nucleotides</i> , 14(1&2):185-194 (1995).	
	DJ	KAWANA, M., <i>et al.</i> , "The deoxygenation of tosylated adenosine derivatives with Grignard reagents," <i>Nucleic Acids Symp. Ser.</i> , 17:37-40 (1986).	
	DK	LAVAIRE, S., <i>et al.</i> , "3'-Deoxy-3'-C-trifluoromethyl nucleosides: Synthesis and antiviral evaluation," <i>Nucleosides &amp; Nucleotides</i> , 17(12):2267-2280 (1998).	
	DL	LEYSEN, P. <i>et al.</i> , "Perspectives for the treatment of infections with <i>Flaviviridae</i> ," <i>Clinical Microbiology Reviews</i> (Washington, D.C.), 13(1):67-82 (January 2000).	
	DM	MARTIN, X., <i>et al.</i> , "Intramolecular hydrogen bonding in primary hydroxyl of thymine 1-(1-deoxy- $\beta$ -D-psicofuranosyl) nucleoside," <i>Tetrahedron</i> , 50(22):6689-6694 (1994).	
	DN	MATSUDA, A., <i>et al.</i> , "Radical deoxygenation of <i>tert</i> -alcohols in 2'-branched-chain sugar pyrimidine nucleosides: Synthesis and antileukemic activity of 2'-deoxy-2'-(S)-methylcytidine," <i>Chem. Pharm. Bull.</i> , 35(9):3967-3970 (1987).	
	DO	MATSUDA, A., <i>et al.</i> , "Alkyl addition reaction of pyrimidine 2'-ketonucleosides: Synthesis of 2'-branched-chain sugar pyrimidine nucleosides (Nucleosides and Nucleotides. LXXXI)," <i>Chem. Pharm. Bull.</i> , 36(3):945-953 (1988).	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/602,136
Filing Date	June 20, 2003
First Named Inventor	Sommadossi <i>et al.</i>
Group Art Unit	Unassigned
Examiner Name	Unassigned

Attorney Docket Number 06171.105074 IDX 1007 DIV

Sheet

5

of

6

3424454 2

## OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. <sup>T<sup>6</sup></sup>
	EA	MATSUDA, A., <i>et al.</i> , "Nucleosides and Nucleotides. 94. Radical deoxygenation of <i>tert</i> -alcohols in 1-(2-C-alkylpentofuranosyl)pyrimidines : Synthesis of (2'S)-2'-deoxy-2'-C-methylcytidine, an antileukemic nucleoside," <i>J. Med. Chem.</i> , 34:234-239 (1991).
	EB	MATSUDA, A., <i>et al.</i> , "Nucleosides and Nucleotides. 104. Radical and palladium-catalyzed deoxygenation of the allylic alcohol systems in the sugar moiety of pyrimidine nucleosides," <i>Nucleosides &amp; Nucleotides</i> , 11(2/4):197-226 (1992).
	EC	MIKHAILOV, S.N., <i>et al.</i> , "Synthesis and properties of 3'C-methylnucleosides and their phosphoric esters," <i>Carbohydrate Research</i> , 124:75-96 (1983).
	ED	MIKHAILOV, S.N., <i>et al.</i> , "Substrate properties of C'-methylnucleoside and C'-methyl-2'-deoxynucleoside 5'-triphosphates in RNA and DNA synthesis reactions catalysed by RNA and DNA polymerases," <i>Nucleosides &amp; Nucleotides</i> , 10(1-3):339-343 (1991).
	EE	MIKHAILOV, S.N., <i>et al.</i> , "Hydrolysis of 2'- and 3'-C-methyluridine 2'c3'-cyclic monophosphates and interconversion and dephosphorylation of the resulting 2'- and 3'-monophosphates: Comparison with the reactions of uridine monophosphates," <i>J. Org. Chem.</i> , 57 (15):4122-4126 (1992).
	EF	NUTT, R.F., <i>et al.</i> , "Branched-chain sugar nucleosides. III. 3'-C-methyladenine", <i>J. Org. Chem.</i> , 33:1789-1795 (1968).
	EG	OIVANEN, M., <i>et al.</i> , "Additional evidence for the exceptional mechanism of the acid-catalyzed hydrolysis of 4-oxopyrimidine nucleosides: Hydrolysis of 1-(1-alkoxyalkyl)uracils, seconucleosides, 3'-C-alkyl nucleosides and nucleoside 3',5'-cyclic monophosphates," <i>J. Chem. Soc. Perkin Trans. 2</i> , 1994:309-314 (1994).
	EH	ONG, S.P., <i>et al.</i> , "Synthesis of 3'-C-methyladenosine and 3'-C-methyluridine diphosphates and their interaction with the ribonucleoside diphosphate reductase from <i>Corynebacterium nephridii</i> ," <i>Biochemistry</i> , 31(45):11210-11215 (1992).
	EI	Oral Session V, Hepatitis C Virus, Flaviviridae; 16 <sup>th</sup> International Conference on Antiviral Research (April 27, 2003, Savannah, Ga.) p A75-77.
	EJ	PAN-ZHOU, X-R, <i>et al.</i> , "Differential effects of antiretroviral nucleoside analogs on mitochondrial function in HepG2 cells," <i>Antimicrob. Agents Chemother.</i> , 44:496-503 (2000).
	EK	ROSENTHAL, A., <i>et al.</i> , "Branched-chain sugar nucleosides. Synthesis of 3'-C-ethyl (and 3'-C-butyl)uridine" <i>Carbohydrate Research</i> , 79:235-242 (1980).
	EL	SAMANO, V., <i>et al.</i> , "Synthesis and radical-induced ring-opening reactions of 2'-deoxyadenosine-2'-spirocyclopropane and its uridine analogue. Mechanistic probe for ribonucleotide reductases," <i>J. Am. Chem. Soc.</i> , 114:4007-4008 (1992).

Examiner Signature		Date Considered
--------------------	--	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

6

of

6

Complete if Known

Application Number	10/602,136
Filing Date	June 20, 2003
First Named Inventor	Sommadossi <i>et al.</i>
Group Art Unit	Unassigned
Examiner Name	Unassigned

Attorney Docket Number

06171.105074 IDX 1007 DIV

3424454 2

## OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. <sup>2</sup>	T <sup>3</sup>
	FA	SAMANO, V., <i>et al.</i> , "Nucleic acid related compounds. 77. 2',3'-Didehydro-2',3'-dideoxy-2'(and 3')-methylnucleosides via [3,3]-sigmatropic rearrangements of 2'(and 3')-methylene-3'(and 2')-O-thiocarbonyl derivatives and radical reduction of a 2'-chloro-3'-methylene analogue," <i>Can. J. Chem.</i> , 71:186-191 (1993).	
	FB	SCHMIT, C., <i>et al.</i> , "The effects of 2'- and 3'-alkyl substituents on oligonucleotide hybridization and stability," <i>Biorganic &amp; Medicinal Chemistry Letters</i> , 4(16):1969-1974 (1994). ["Altmann"]	
	FC	SERAFINOWSKI, P.J., <i>et al.</i> , "New method for the preparation of some 2'- and 3'-trifluoromethyl-2',3'-dideoxyuridine derivatives," <i>Tetrahedron</i> (Elsevier Science Publishers), 56(2):333-339 (1999).	
	FD	SHARMA, P.K., <i>et al.</i> , "Synthesis of 3'-trifluoromethyl nucleosides as potential antiviral agents," <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 19(4):757-774 (2000).	
	FE	SOMMADOSSI J-P., <i>et al.</i> , "Comparison of cytotoxicity of the (-)- and (+)-enantiomer of 2',3'-dideoxy-3'-thiacytidine in normal human bone marrow progenitor cells" <i>Biochemical Pharmacology</i> , 44:1921-1925 (1992).	
	FF	SOMMADOSSI J-P., <i>et al.</i> , "Toxicity of 3'-azido-3'-deoxythymidine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine for normal human hematopoietic progenitor cells in vitro" <i>Antimicrobial Agents and Chemotherapy</i> , 31:452-454 (1987).	
	FG	TRITSCH, D., <i>et al.</i> , "3'-β-ethynyl and 2'-deoxy-3'-β-ethynyl adenosines: First 3'-β-branched adenosines substrates of adenosine deaminase," <i>Bioorganic &amp; Medicinal Chemistry Letters</i> , 10:139-141 (2000).	
	FH	TUNITSKAYA, V.L., <i>et al.</i> , "Substrate properties of C'-methyl UTP derivatives in T7 RNA polymerase reactions. Evidence for N-type NTP conformation," <i>FEBS Letters</i> , 400:263-266 (1997).	
	FI	USUI, H., <i>et al.</i> , "Synthesis of 2'-deoxy-8,2'-ethanoadenosine and 3'-deoxy-8,3'-ethanoadenosine (Nucleosides and Nucleotides. LXIV)," <i>Chem. Pharm. Bull.</i> , 34(1):15-23 (1986).	
	FJ	WALCZAK, K., <i>et al.</i> , "Synthesis of 1-(3-alkyl-2,3-dideoxy-D-pentofuranosyl)uracils with potential anti-HIV activity," <i>Acta Chemica Scand.</i> , 45:930-934 (1991).	
	FK	WALTON, E., <i>et al.</i> , "Branched-chain sugar nucleosides. V. Synthesis and antiviral properties of several branched-chain sugar nucleotides," <i>J. Med. Chem.</i> , 12:306-309 (1969).	
	FL	WOLFE, M.S., <i>et al.</i> , "A concise synthesis of 2'-C-methylribonucleosides," <i>Tetrahedron Letters</i> , 36(42):7611-7614 (1995).	
	FM	WU, J.-C., <i>et al.</i> , "A new stereospecific synthesis of [3.1.0] bicyclic cyclopropano analog of 2',3'-dideoxyuridine, <i>Tetrahedron</i> , 46(7):2587-2592 (1990).	

Examiner Signature		Date Considered
--------------------	--	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application No.:	10/602,136	Confirmation No.:	Unassigned
Applicant:	Sommadossi <i>et al.</i>		
Filed:	June 20, 2003		
TC/A.AU.:	Unassigned		
Examiner:	Unassigned		
Docket No.:	06171.105074 IDX 1007 DIV		
Customer No.:	20786		
Title:	Methods and Compositions for Treating Hepatitis C Virus		

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

**REFERENCES**

**BOX 1 OF 2**